Health Condition 1: L811- Chloasma Health Condition 2: O- Medical and Surgical
Conditions
Interventions
Intervention1: tranexamic acid: 20 patients will be given oral tranexamic acid 250 mg twice a day for 12 weeks and in 20 patients cycles of intradermal microinjection with tranexamic acid will be give
Sponsors
Department of Dermatology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with clinical diagnosis of melasma. 2. Patients above the age of 18 years and below the age of 50 years.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of bleeding disorders 2. Patient taking oral anticoagulants, hormonal drugs like estrogen, progesterone, oral contraceptive pills and other female hormonal analogues. 3. Patients with past history of thrombotic disease like DVT. 4. Patients with family history of thrombotic disease. 5. Patients with known allergy to tranexamic acid. 6. Pregnant and lactation mothers. 7. Patients using photosensitizing drugs such as nonsteroidal anti-inflammatory drugs, tetracycline, spironolactone, phenytoin, carbamazepine, use of other depigmenting oral or topical agents. 8. Patients with any other facial dermatoses. 9. Patients with a history of any treatment for melasma in the past 6 months. 10. Patients with significant systemic illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the clinical efficacy of oral and intralesional tranexamic acid in treatment of melasma.Timepoint: at 4, 8 and 12 weeks than follow up at 16, 20 and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| NOT APPLICABLETimepoint: NOT APPLICABLE | — |
Countries
India
Contacts
Public ContactDR GP THAMI
Govt Medical College and Hospital
Outcome results
None listed